Immunophotonics has announced a collaboration with The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) around a phase 2/3 clinical trial.
The trial is designed in collaboration with a Steering Committee nominated by CIRSE and managed by CIRSE’s contract research organisation, Next Research. This trial, entitled INJECTABL-3, will be a clinical trial conducted in two phases and is expected to enrol an estimated 300–500 patients in a randomised, controlled study in the USA and Europe. This pivotal trial will evaluate the safety and efficacy of Immunophotonics’s lead clinical asset, IP-001, in combination with ablation treatments in key indications where tumour ablation is the current standard of care.
Philippe L Pereira (SLK-Kliniken, Stuttgart, Germany)—incoming president of CIRSE, commented: “The collaboration between Immunophotonics, CIRSE, and Next Research highlights the importance of multidisciplinary partnerships in advancing major medical breakthroughs for patients in need. Tumour recurrence following radical tumour ablation is a major unmet medical need, and Immunophotonics’s novel approach is not only practical for clinicians and patients, but early data indicates it has tremendous promise.”
“This partnership signifies an important step in advancing the emerging field of interventional immuno-oncology,” remarked Nathalie Kaufmann, chief operating officer at Next Research. “It’s just the start, and we look forward to combining the expertise of our organisations to advancing the potential of IP-001.”
Uwe Martens (SLK-Clinics Heilbronn, Heilbronn, Germany) and future principal investigator of the INJECTABL-3 study, stated, “We are looking forward to playing a part in the INJECTABL-3 trial and seeing the potential for IP-001 to become a game-changing treatment option for patients that receive tumour ablation. Early data demonstrates tolerability of the investigational product along with promise in terms of IP-001’s ability to drive abscopal effects. This type of immune-mediated response could be quite beneficial for patients, and therefore it will be important to conduct this clinical trial.”
“Immunophotonics is dedicated to transforming routine tumour destruction techniques, such as ablation, into something much more powerful for patients,” said Lu Alleruzzo, chief executive officer and co-founder of Immunophotonics. “Ablation will liberate tumour information that IP-001 will use to drive a systemic tumour specific immune response. Our clinical data thus far demonstrates the potential of our technology, and we are thrilled to be collaborating with the global clinical experts at CIRSE and Next Research on INJECTABL-3. I believe that together we will forever change the way cancer is treated.”
